News

/News

Metrion appoints two new Board Directors

2018-03-09T15:46:44+00:00

Dr Barry Kenny joins as Non-Executive Director Dr Andrew Southan, COO, appointed Executive Director Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. The appointments have been made to strengthen the Company’s focus [...]

Metrion appoints two new Board Directors 2018-03-09T15:46:44+00:00

Metrion Biosciences establishes Scientific Advisory Board

2018-03-09T16:01:50+00:00

Scientific Advisory Board will provide scientific oversight and strategic advice to support Metrion’s ion channel screening, cardiac safety testing, and native tissue and human stem cell translational assays. Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that it has established a Science Advisory Board (SAB) to provide [...]

Metrion Biosciences establishes Scientific Advisory Board 2018-03-09T16:01:50+00:00

Innovate UK Biomedical Catalyst Feasibility Award

2018-07-18T16:02:11+00:00

Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst Feasibility Award Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease Project forms the first of a series designed to deliver proof of concept data on immune-sparing drug candidates Project will further enhance Metrion’s ion channel drug discovery [...]

Innovate UK Biomedical Catalyst Feasibility Award 2018-07-18T16:02:11+00:00

Novel potassium channel inhibitors acquired from Japan Tobacco Inc.

2018-04-13T13:35:54+00:00

Acquired intellectual property rights have potential application in a variety of clinical indications, including auto-immune disorders and neurodegenerative diseases. Metrion now owns all patented and unpatented IP developed during previous collaboration between Metrion and Japan Tobacco Inc. Cambridge, UK, 29 January 2018: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery [...]

Novel potassium channel inhibitors acquired from Japan Tobacco Inc. 2018-04-13T13:35:54+00:00

Metrion collaborates with Candidate Biopharma Advisors

2018-03-09T15:58:44+00:00

Metrion Biosciences today announced a collaboration with Chris Mathes PhD, founder of Candidate Biopharma Advisors, to broaden Metrion's exposure in the North American market. Chris is well qualified to promote Metrion's excellence in ion channel drug discovery, safety profiling and translational assays. Like the majority of our staff, he started his career as a conventional [...]

Metrion collaborates with Candidate Biopharma Advisors 2018-03-09T15:58:44+00:00

Metrion Biosciences opens SyndicateRoom investment round

2018-03-09T15:53:46+00:00

Cambridge, UK, 16 January 2018: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and online investment platform SyndicateRoom, announced today the opening of a £600k investment round in Metrion. Metrion will use the funds to expand its rapidly growing fee-for-service business. This is the first private investment round for [...]

Metrion Biosciences opens SyndicateRoom investment round 2018-03-09T15:53:46+00:00

Metrion Biosciences 2017 review

2018-01-12T11:36:06+00:00

Thanks to our Customers: the Metrion Biosciences team would like to thank our customers for placing business with us in 2017. We take great pride in providing a high-quality service to advance early stage drug discovery research for our clients, whether it be integrated drug discovery, new target screening, stand-alone safety profiling and/or translational assay [...]

Metrion Biosciences 2017 review 2018-01-12T11:36:06+00:00

Metrion Biosciences announce collaboration with LifeArc

2018-01-29T16:44:05+00:00

LifeArc and Metrion Biosciences extend partnership agreement to support LifeArc's neuroscience small molecule drug discovery programme. Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, the UK medical research charity previously known as MRC Technology, today announced an extension of  their existing partnership, to support LifeArc’s neuroscience drug discovery [...]

Metrion Biosciences announce collaboration with LifeArc 2018-01-29T16:44:05+00:00

Q2 2017 review

2017-08-31T15:30:11+00:00

Q2 2017 was another productive quarter for the Metrion Biosciences team. Our stand-alone CRO sales continued on an upward trajectory, with both April and June revenues beating our previous best months for invoiced sales and total H1 2017 stand-alone CRO revenue being well above our 2016 figure. Our FTE-based collaborations also performed well, delivering high quality [...]

Q2 2017 review 2017-08-31T15:30:11+00:00